Literature DB >> 12080356

Thrombotic thrombocytopenic purpura and hemolytic uremic syndrome following allogeneic bone marrow transplantation.

H Takatsuka1, T Wakae, A Mori, M Okada, A Suehiro, T Okamoto, E Kakishita.   

Abstract

We monitored the levels of various cytokines and chemokines, as well as an adhesion molecule and factors related to vascular endothelial damage, in three patients with thrombotic thrombocytopenic purpura and hemolytic uremic syndrome after bone marrow transplantation. Measurements were done at the onset of this condition and during plasma exchange for treatment. At the onset of thrombotic thrombocytopenic purpura and hemolytic uremic syndrome, the levels of interleukin-8, thrombomodulin, and plasminogen activator inhibitor-1 were all markedly increased. A close relationship was observed between improvement in symptoms by plasma exchange and a decrease in interleukin-8 level, suggesting that this chemokine may be related to the development of thrombotic thrombocytopenic purpura and hemolytic uremic syndrome after bone marrow transplantation.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12080356     DOI: 10.1038/sj.bmt.1703565

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN: 0268-3369            Impact factor:   5.483


  3 in total

Review 1.  Advances in the diagnosis and treatment of disseminated intravascular coagulation in haematological malignancies.

Authors:  Takayuki Ikezoe
Journal:  Int J Hematol       Date:  2020-09-09       Impact factor: 2.490

Review 2.  Thrombotic microangiopathy in haematopoietic stem cell transplantation: diagnosis and treatment.

Authors:  Cecilia M Choi; Alvin H Schmaier; Michael R Snell; Hillard M Lazarus
Journal:  Drugs       Date:  2009       Impact factor: 9.546

3.  Markers of coagulation activation and acute kidney injury in patients after hematopoietic cell transplantation.

Authors:  S R Hingorani; K Seidel; E Pao; R Lawler; G B McDonald
Journal:  Bone Marrow Transplant       Date:  2015-02-09       Impact factor: 5.483

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.